Runway and evidence finance book / 15 August 2026
Pharma and Life Sciences CFO Jobs in London: finance the next answer, not hope
Pharma and Life Sciences CFO Jobs in London demand a finance leader who connects scientific evidence, trial commitments, tax, pricing and capital markets without turning uncertain development into a falsely precise valuation.
Runway bridge
The month cash ends matters less than the decisions that arrive first
| Decision date | Cash exposure | CFO evidence |
|---|---|---|
| Study initiation | Sites, vendors, supply and non-cancellable commitments begin | Approved protocol, enrolment scenario and contract map |
| Interim evidence | Continue, adapt, stop or expand changes the burn path | Predeclared decision gate and bounded scenarios |
| Manufacturing slot | Capacity may require cash before clinical certainty | Demand, shelf life, alternatives and failure cost |
| Financing window | Market access and dilution vary around results | Minimum cash, option, disclosure and fallback |
| Licence milestone | Receipt or payment depends on technical interpretation | Contract trigger, judgement and counterparty position |
| Going concern review | Forecast, mitigating action and disclosure converge | Supportable scenarios rather than one management case |
A runway number can conceal when the company loses the ability to choose. The CFO should connect cash with evidence gates, obligations and financing lead time, then show directors which action preserves an option. Scientific probability is not a treasury instrument, and a promising signal is not cash until a transaction is executed.
Candidate evidence should include a scenario that changed strategy. Name the original assumption, updated evidence, capital consequence, recommendation and what the board chose. Avoid presenting a favourable market outcome as proof that the earlier decision had no risk.
Value architecture
Five finance models must reconcile without pretending to be one
When commitments, receipts and contingencies change liquidity and choice.
What each study costs, learns and enables under delay, redesign or stop.
How probability, timing, price, access and competition create conditional value.
How contracts, milestones, R&D, intangibles and obligations enter reported results.
How relief, pricing schemes and jurisdiction affect realised cash and margin.
These models answer different questions. A probability-adjusted valuation cannot replace a going-concern cash forecast; an accounting conclusion cannot establish technical success; a tax credit forecast requires eligibility and process. The CFO creates traceable bridges, not a blended spreadsheet whose apparent agreement hides incompatible definitions.
R&D relief control
A forecast tax credit begins with qualifying activity, not the budget label
Identify the project
Establish the scientific or technological uncertainty and the work seeking an advance.
Map expenditure
Connect staff, contractors, consumables, data and other costs with current qualifying rules.
Select the scheme
Assess merged RDEC or ERIS eligibility for the accounting period without double claiming.
Test restrictions
Review contractor, overseas, subsidy, PAYE-cap and company-status effects as applicable.
Meet process
Address notification, additional information, return and sign-off requirements on time.
Preserve evidence
Keep technical and financial records that reconcile to the claim and withstand enquiry.
For periods beginning on or after 1 April 2024, the merged RDEC and Enhanced R&D Intensive Support schemes replaced the former RDEC and SME schemes. The same expenditure cannot sit in both. The CFO should treat current HMRC guidance and specific advice as the basis, not a historic percentage or adviser estimate copied into liquidity.
Current market record
Zero Charters means no opening, runway claim or GBP benchmark
No comparable London life sciences CFO Charter is live.
No defensible median is available.
Finance, life sciences and London banks are available.
Band 2 CFO and London Band A.
Pharma and Life Sciences CFO Jobs in London appear only through authorised Charters. Public accounts, fundraisings and trial updates do not permit this page to infer a current appointment, private forecast or financing need. NHS, venture-backed, listed and multinational roles are not collapsed into one pay series.
UK medicine economics
The 2026 VPAG headline rate belongs inside a product-specific bridge
The published 2026 VPAG headline payment percentage for newer medicines is 14.5%. That fact does not mean every UK medicine pays the same effective amount. Product age, exemptions, scheme membership, measured sales, amendments and specific commercial arrangements matter.
The CFO should bridge gross sales to net realised economics by product and channel. Price, scheme payment, patient-access arrangement, distribution, returns, inventory, tax and currency need consistent definitions. A headline invoice price does not describe NHS net revenue.
Forecast access with evidence and operational uptake. Regulatory authorisation, NICE recommendation, commissioning, formulary adoption, supply and eligible patient identification are distinct events. The model should show dependency rather than place all value on a single launch date.
Candidate proof may use a bounded product class and percentage-free bridge. Show how a scheme update changed forecast, investment or contract choice. Never import confidential commercial-access terms from another company into assessment.
The shortlist of models
How London life sciences CFOs reach confidential mandates
Gladwin International & Company publishes this page and explains The Executive Passport first. Four established firms follow as a neutral capability-based selection without rating or endorsement.
Consent-led matching
The Executive Passport, Gladwin International & Company
The Executive Passport is a private board and C-suite exchange. Its 60-item assessment intersects CFO leadership with pharmaceuticals and life sciences and London context across runway, portfolio allocation, R&D tax, trials, controls, pricing, access, financing and board counsel. Blind Match can communicate relevant verified decisions after removing identity, employer and declared conflicts. The holder reads the named company's Mandate Charter before choosing whether a Consent Passport moves; later evidence remains controlled. Unpublished results, participant information, inside forecasts, tax files, regulator correspondence and deal terms are excluded from matching. Recruiters cannot browse members. Annual membership is INR 3,75,000 under CFO Band 2 and London Band A. The fee supports assessment, verification and twelve months in the exchange; it offers no priority, interview right or appointment assurance. The company retains technical accounting, tax, regulatory, reference and governance diligence.
See how The Executive Passport worksOther firms operating in this marketFour firms, presented without rank or score
Spencer Stuart
A global retained-search firm with published CFO, life sciences and board capabilities.
Russell Reynolds Associates
A global leadership adviser covering finance officers, biopharma and succession.
Egon Zehnder
A global partnership with finance, life sciences and assessment work.
Korn Ferry
A global organisational consulting and search firm spanning CFO and life sciences leadership.
Finance evidence kit
Bring six decisions, not a confidential board pack
Runway
A scenario changed the timing or scope of a portfolio commitment.
Financing
A capital option balanced continuity, dilution, covenant and evidence timing.
R&D tax
Eligibility and documentation changed a claim or cash assumption.
Pricing and access
Gross-to-net and uptake evidence altered an investment or launch choice.
Control
A trial, vendor, milestone or close weakness received durable remediation.
Disclosure
Finance translated uncertainty without promoting an unsupported scientific story.
For each, state company type, decision, authority, evidence, alternatives, outcome and later learning. Use ranges only when authorised and non-identifying. A referee can verify counsel and behaviour without receiving the underlying model.
Control perimeter
Clinical vendors create finance obligations before invoices arrive
| Exposure | Finance control | Executive question |
|---|---|---|
| Site and CRO activity | Contract, enrolment, visit, accrual and change reconciliation | Does spend reflect work performed and latest study plan? |
| Manufacturing | Batch, yield, release, expiry, capacity and cancellation commitment | Which cash is at risk if evidence or timing changes? |
| Safety and regulation | Complete resourcing, escalation and contingent obligation | Can delivery pressure defer a required action? |
| Licence milestone | Trigger interpretation, probability, counterparty and accounting | Are cash, revenue and disclosure using the same fact? |
| Data and systems | Access, validation, change, completeness and close dependency | Can finance rely on the operational record? |
The CFO should not direct clinical conduct, but must ensure commitments, accruals, controls and risks are visible. A smooth close cannot compensate for a weak operational source. Strong candidates show how finance entered the process early enough to improve the evidence rather than adjusting after the event.
Ask how the leader reconciled investigator forecasts with actual site activity, challenged a change order and kept the clinical owner accountable for operational truth. The answer should cover cut-off, currency, disputes, subsequent events and the point at which a forecast difference became a board risk. Evidence of finance partnership is not that the study stayed on budget. It is that directors understood the cash consequence of the current clinical plan while there was still time to choose.
Direct candidate answers
Questions life sciences finance leaders ask before moving
Are London life sciences CFO jobs public?+
Some listed, private and venture-backed roles are announced, while financing, transaction, founder-transition and incumbent searches often start confidentially.
Only an authorised Charter establishes an opening here; company cash, trial news or an auditor change does not.
What does a life sciences CFO earn in London?+
No GBP range appears because zero comparable Charters are published. Pre-revenue equity, listed-company incentives, affiliate packages and services businesses require different peers.
Benchmark after stage, listing, runway, portfolio, geography and transaction responsibility are known.
What is different about a biotech CFO?+
Value and cash depend on uncertain evidence, staged trials, quality, manufacturing, licences and financing. Traditional revenue forecasting may be secondary before commercialisation.
The CFO must translate scientific choices into scenarios without pretending that a probability model removes uncertainty.
What is the 2026 VPAG headline payment percentage?+
The published 2026 headline payment percentage for newer medicines under the voluntary scheme is 14.5%. The scheme and later amendments should be read for the exact product and company treatment.
A CFO should not apply the headline rate indiscriminately across products, schemes or contractual arrangements.
Which UK R&D tax-relief schemes matter in 2026?+
For accounting periods beginning on or after 1 April 2024, the merged RDEC scheme and Enhanced R&D Intensive Support replaced the old RDEC and SME schemes. Eligibility, expenditure, notification and claim rules require current analysis.
The same expenditure cannot be claimed under both schemes, and a forecast credit should not be treated as unrestricted cash before qualification and process are verified.
How should a CFO model clinical development?+
Use stage-specific spend, timing, evidence gates, enrolment, vendors, supply, currency and contingency. Show base, delay, redesign, stop and partner scenarios.
Do not collapse technical probability, regulatory timing and commercial value into one unexplained percentage.
Does the CFO own R&D prioritisation?+
Not alone. Scientific, medical and regulatory leaders establish evidence and patient consequences; the CEO and board allocate enterprise capital. The CFO makes assumptions, options and runway consequences comparable.
The Charter should name recommendation and approval rights.
Can a technology CFO move into life sciences?+
Potentially, especially with capital markets, scaling and subscription or platform experience, but trial accounting, R&D relief, quality, manufacturing, licensing and evidence-driven value require explicit testing.
A learning plan and strong technical team are part of the transfer case.
Can I explore the role confidentially?+
Yes. Blind Match can expose bounded financing, portfolio and control evidence after hiding name, employer and conflicts. You inspect the named company and Charter before identity release.
Exclude unpublished results, participant data, forecasts containing inside information, tax files and deal terms.
How long does a life sciences CFO search take?+
Ten to sixteen weeks to preferred candidate is a reasonable indicative range after mandate agreement. Global mapping, audit or investor panels, cases, references and notice may extend it.
A financing deadline should not create informal CFO authority.
Which firms recruit life sciences CFOs?+
Spencer Stuart, Russell Reynolds Associates, Egon Zehnder and Korn Ferry publish CFO, life sciences or board capabilities relevant to London. The set is neutral and unranked.
The Executive Passport appears first because its publisher is disclosing its own model.
What does a London CFO Passport cost?+
Annual membership is INR 3,75,000 under CFO Band 2 and London Band A. It covers assessment, verification and twelve months of consent-led matching.
It cannot buy priority, interview or appointment.
How should I evidence a financing decision?+
Show runway scenarios, evidence calendar, alternatives, dilution or covenant effects, board recommendation, execution and later consequence. State the assumptions known at the time.
Remove confidential terms and market-sensitive forecasts, and separate your authorship from board and adviser decisions.
What should I inspect before accepting?+
Review cash scenarios, portfolio commitments, clinical accruals, tax-relief claims, controls, audit issues, IP and licence economics, manufacturing obligations, VPAG exposure, disclosure and financing plans.
Ask which material fact is unresolved and who owns it through transition.
Acceptance balance sheet
Test eight hidden liabilities before taking the finance chair
Reconcile cash with committed trials, manufacturing, licences, leases, tax, restructuring and minimum operating capability. Inspect the scenarios behind going concern and the dates when mitigating actions must become executable.
Review close and consolidation, clinical accruals, revenue or milestone judgements, R&D tax processes, audit findings, systems and segregation. Ask which control depends on a single person or spreadsheet and what remediation is funded.
Understand portfolio evidence only to the level needed for finance accountability, with qualified scientific and medical leaders present. Test how bad news reaches forecast, disclosure and financing. Verify material VPAG, access, IP, vendor and transaction assumptions through controlled diligence.
No comparable Charters means no GBP range. Once the mandate is real, benchmark salary, pension, bonus, long-term equity, buyout, severance and change-of-control terms against truly similar company stages and risks. Complete references and approvals before resignation; do not act as informal CFO during notice.
Ask the chair how unresolved audit, financing and portfolio matters will transfer. A responsible handover names owners, deadlines, evidence and the point at which the incoming CFO acquires authority. Information shared during notice should serve diligence, not create shadow accountability.
Evidence register
Primary 2026 finance framework basis for this life sciences CFO file
DHSC 2024 VPAG materials including the May 2026 update and published 2026 headline percentage, HMRC merged RDEC and ERIS guidance updated in 2026, MHRA clinical-trial transition guidance, and current NICE technology-appraisal materials were consulted on 15 August 2026. Firm inclusion is unranked and based on published relevant capabilities.